摘要目的:探讨奥曲肽联合双歧杆菌三联活菌肠溶胶囊治疗急性胰腺炎的临床效果及其对患者肠黏膜屏障功能的影响。方法:将2019年1月至2021年2月河南省郑州大学第一附属医院收治的132例急性胰腺炎患者作为研究对象，按随机数字表法将分为对照组（66例，奥曲肽治疗）和观察组（66例，奥曲肽联合双歧杆菌三联活菌肠溶胶囊治疗），均治疗7 d。比较两组临床症状缓解时间、临床疗效、治疗前后肠黏膜屏障功能、血清胰酶水平及不良反应情况。结果:与对照组比较，观察组患者腹痛、呕吐、发热症状缓解时间及血、尿淀粉酶恢复时间均明显缩短（均 P<0.05）。观察组患者治疗总有效率高于对照组（ P<0.05）。治疗后，两组患者血清内毒素、血浆D-乳酸、二胺氧化酶（DAO）及血清淀粉酶（AMY）、脂肪酶（LIPA）水平均低于治疗前，其中观察组更低（均 P<0.05）。两组总不良反应发生率比较，差异无统计学意义（ P>0.05）。 结论:奥曲肽联合双歧杆菌三联活菌肠溶胶囊可明显降低急性胰腺炎患者血清AMY、LIPA水平，增强肠黏膜屏障功能，改善腹痛、发热等症状，安全有效。

abstractsObjective:To investigate the clinical efficacy of octreotide combined with bifidobacterium triple viable enteric-coated capsules in treatment of acute pancreatitis and its effect on the intestinal mucosal barrier function.Methods:A total of 132 patients with acute pancreatitis admitted to the First Affiliated Hospital of Zhengzhou University of Henan Province between January 2019 and February 2021 were included and were assigned to the control group ( n=66, given octreotide) and the study group ( n=66, given octreotide and bifidobacterium triple viable enteric-coated capsules) according to random number table. The treatment duration was seven days in either group. The two groups were then compared for time to relief of clinical symptoms, clinical efficacy, intestinal mucosal barrier function at baseline and after treatment, serum pancreatic enzymes and adverse reactions. Results:Compared with the control group, the time to symptomatic relief of abdominal pain, vomiting, and fever and the time to restore normal levels of blood and urine amylase (AMY) were significantly shortened in the study group (all P<0.05) . The total response rate was higher in patients of the study group compared with the control group ( P<0.05) . After treatment, either group showed reductions in serum levels of endotoxin, plasma D-lactic acid, diamine oxidase (DAO) , AMY, and lipase (LIPA) from baseline, and the reduction was even greater in the study group compared with the control group (all P<0.05) . There was no significant difference in overall incidence of adverse reactions between the two groups ( P>0.05) . Conclusion:In patients with acute pancreatitis, octreotide plus bifidobacterium triple viable enteric-coated capsules can significantly reduce serum AMY and LIPA levels, enhance the intestinal mucosal barrier function, relief symptoms such as abdominal pain and fever, and is clinically safe and effective.